PCYT1A and neoplasm: These myoCAFs drive resistance via TFE3‐mediated autophagy and PCYT1A‐led phosphatidylcholine overproduction, creating a phospholipid‐rich niche that activates tumor HSP90/HIF1A, promoting stemness and revealing actionable therapeutic targets for HSPC.